← Back to Search

Monoclonal Antibodies

Belantamab for Lupus

Phase 1
Recruiting
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Moderate to Severe SLE disease
Positive anti-dsDNA autoantibody test results
Must not have
Any acute, severe lupus related flare during the Screening Period that needs immediate treatment
Has any unstable or progressive manifestation of SLE
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see how safe and well-tolerated belantamab is for people with moderate to severe lupus. It will also study how belantamab levels change in the body

Who is the study for?
This trial is for men and women aged 18 to 75 who have moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.
What is being tested?
The study is testing the safety of belantamab, a medication given through an IV infusion, in treating SLE. It will also monitor how the drug's levels change in the body over time and how the body responds to it.
What are the potential side effects?
While specific side effects are not listed, common ones for new medications like belantamab could include reactions at the infusion site, allergic responses, fatigue, headaches, or changes in blood counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lupus is moderate to severe.
Select...
I have tested positive for anti-dsDNA antibodies.
Select...
I have been diagnosed with lupus according to EULAR or ACR criteria.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a severe lupus flare-up recently that required immediate treatment.
Select...
My lupus symptoms are getting worse.
Select...
My lupus has caused permanent damage to one or more of my organs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BelantamabExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,807 Previous Clinical Trials
8,381,302 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top